[{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":1.05,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.05,"dosageForm":"Topical Cream","sponsorNew":"Torii Pharmaceutical \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Shionogi"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Nogra Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NAC-GED-0507","moa":"PPA-gamma receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Torii Pharmaceutical \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Film-Forming Solution","sponsorNew":"Torii Pharmaceutical \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Topical Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Topical Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Topical Film-Forming Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Torii Pharmaceutical","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Topical Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Torii Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The agreement aims to initiate a global pivotal Phase 3 clinical trial of Verrica’s product, Ycanth (cantharidin), for the treatment of common warts.

                          Product Name : Ycanth

                          Product Type : Other Small Molecule

                          Upfront Cash : $11.5 million

                          July 01, 2025

                          Lead Product(s) : Cantharidin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Verrica Pharmaceuticals

                          Deal Size : $29.5 million

                          Deal Type : Collaboration

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The two companies would strengthen its domestic business by strengthening sales and marketing channels in dermatology including Vtama (tapinarof), paediatrics, and otolaryngology.

                          Product Name : Vtama

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 07, 2025

                          Lead Product(s) : Tapinarof

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Shionogi

                          Deal Size : $1,050.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : TO-208 previously known as VP-102 is a single-use drug device combination product containing (cantharidin) topical solution. It is being evaluated for the treatment of Molluscum Contagiosum.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 06, 2024

                          Lead Product(s) : Cantharidin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Verrica Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Through the licensing agreement with Torii Pharmaceutical, to jointly conduct a global pivotal Phase 3 clinical trial studies of Ycanth (cantharidin) for the treatment of common warts.

                          Product Name : Ycanth

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 15, 2024

                          Lead Product(s) : Cantharidin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Verrica Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the agreement, Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan for the treatment of acne vulgaris. NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of ...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 26, 2023

                          Lead Product(s) : NAC-GED-0507

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Recipient : Nogra Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.

                          Product Name : Ycanth

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 08, 2022

                          Lead Product(s) : Cantharidin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Verrica Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Oral, once-daily ORLADEYO was approved in Japan in January 2021 for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

                          Product Name : Orladeyo

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 14, 2021

                          Lead Product(s) : Berotralstat HCl

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Recipient : BioCryst Pharmaceuticals

                          Deal Size : $15.0 million

                          Deal Type : Collaboration

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted adm...

                          Product Name : Ycanth

                          Product Type : Other Small Molecule

                          Upfront Cash : $11.5 million

                          March 17, 2021

                          Lead Product(s) : Cantharidin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Verrica Pharmaceuticals

                          Deal Size : $69.5 million

                          Deal Type : Licensing Agreement

                          blank

                          09

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The agreement grants Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.

                          Product Name : Ycanth

                          Product Type : Other Small Molecule

                          Upfront Cash : $11.5 million

                          May 08, 2020

                          Lead Product(s) : Cantharidin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Verrica Pharmaceuticals

                          Deal Size : $70.0 million

                          Deal Type : Agreement

                          blank

                          10

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Torii Pharmaceutical will pay tiered royalties of up to 40 percent of Japanese net sales of berotralstat to BioCryst upon receipt of a reimbursement price approval NHI Japan.

                          Product Name : Orladeyo

                          Product Type : Other Small Molecule

                          Upfront Cash : $22.0 million

                          March 02, 2020

                          Lead Product(s) : Berotralstat HCl

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Recipient : BioCryst Pharmaceuticals

                          Deal Size : $42.0 million

                          Deal Type : Agreement

                          blank